SECT-B Stock Analysis: Sectra (publ) | ST
Medical Devices | ST, Sweden | Market Cap: 54.486m SEK | 12M Return: -20.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 36.7M
EPS Trend: 80.6%
Qual. Beats: 0
Rev. Trend: 95.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sectra AB (publ) is a Swedish technology company founded in 1957 and headquartered in Linköping. It operates across two main sectors-medical imaging IT and secure communications-with customers primarily consisting of hospitals, private clinic chains, and security-sensitive public-sector organizations in Sweden, the UK, the Netherlands, and elsewhere in Europe.
The company runs three business segments. Imaging IT Solutions provides medical imaging management systems, including PACS (picture archiving and communication systems) used by healthcare providers to store, view, and share diagnostic images such as X-rays, MRIs, and CT scans. Secure Communications offers encrypted voice and data communication products, often serving defense, government, and critical infrastructure clients. Business Innovation develops niche medical IT products, including orthopedic surgery planning tools, medical education platforms, and IT support for precision cancer diagnostics.
Listed on Nasdaq Stockholm under the ticker SECT-B, Sectra is a mid-cap company competing in the European medical imaging IT market alongside larger international healthcare technology vendors. The revenue model combines upfront system sales with recurring maintenance, support, and managed-service contracts tied to long-term relationships with hospital customers, providing a degree of revenue visibility uncommon in pure hardware businesses.
- Imaging IT recurring revenue and order intake expand across European hospitals
- Secure Communications secures new European defense and public safety contracts
- Subscription mix shift lifts operating margins and strengthens earnings visibility
| Net Income: 563.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA 0.44 > 1.0 |
| NWC/Revenue: 38.07% < 20% (prev 38.82%; Δ -0.75% < -1%) |
| CFO/TA 0.25 > 3% & CFO 1.10b > Net Income 563.8m |
| Net Debt (-1.63b) to EBITDA (778.8m): -2.09 < 3 |
| Current Ratio: 1.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (192.7m) vs 12m ago 0.00% < -2% |
| Gross Margin: 35.95% > 18% (prev 88.65%; Δ -52.71% > 0.5%) |
| Asset Turnover: 86.07% > 50% (prev 86.25%; Δ -0.18% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| DSRI: 0.44 (Receivables 722.3m/1.51b, Revenue 3.54b/3.24b) |
| GMI: 2.47 (GM 88.65% / 35.95%) |
| AQI: 0.99 (AQ_t 0.12 / AQ_t-1 0.13) |
| SGI: 1.09 (Revenue 3.54b / 3.24b) |
| TATA: -0.12 (NI 563.8m - CFO 1.10b) / TA 4.47b) |
| Beneish M = -2.11 (Cap -4..+1) = BB |
As of July 11, 2026, the stock is trading at SEK 282.40 with a total of 83,172 shares traded. Over the past week, the price has changed by -4.53%, over one month by -9.37%, over three months by +20.07% and over the past year by -20.58%.
Current recommended Stop Loss: 262.10 (which is 7.2% or 2 ATR below the current price).
Sectra (publ) has no consensus analysts rating.
P/E Trailing = 96.5188
P/E Forward = 71.4286
P/S = 14.966
P/B = 26.6518
Revenue TTM = 3.54b SEK
EBIT TTM = 695.3m SEK
EBITDA TTM = 778.8m SEK
Long Term Debt = 81.7m SEK (from longTermDebtTotal, two quarters ago)
Short Term Debt = 21.0m SEK (from shortTermDebt, last quarter)
Debt = 179.2m SEK (corrected: LT Debt 81.7m + ST Debt 21.0m) + Leases 76.5m
Net Debt = -1.63b SEK (calculated: Debt 179.2m - CCE 1.81b)
Enterprise Value = 52.9b SEK (54.5b + Debt 179.2m - CCE 1.81b)
Interest Coverage Ratio = unknown (Ebit TTM 695.3m / Interest Expense TTM 0.0)
EV/FCF = 53.53x (Enterprise Value 52.9b / FCF TTM 987.3m)
FCF Yield = 1.87% (FCF TTM 987.3m / Enterprise Value 52.9b)
FCF Margin = 27.88% (FCF TTM 987.3m / Revenue TTM 3.54b)
Net Margin = 15.92% (Net Income TTM 563.8m / Revenue TTM 3.54b)
Gross Margin = 35.95% ((Revenue TTM 3.54b - Cost of Revenue TTM 2.27b) / Revenue TTM)
Gross Margin QoQ = 20.50% (prev 22.55%)
Tobins Q-Ratio = 11.81 (Enterprise Value 52.9b / Total Assets 4.47b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 179.2m)
Taxrate = 22.66% (165.2m / 728.9m)
NOPAT = 537.7m (EBIT 695.3m * (1 - 22.66%))
Current Ratio = 1.61 (Total Current Assets 3.56b / Total Current Liabilities 2.21b)
Debt / Equity = 0.08 (Debt 179.2m / totalStockholderEquity, last quarter 2.14b)
Debt / EBITDA = -2.09 (Net Debt -1.63b / EBITDA 778.8m)
Debt / FCF = -1.65 (Net Debt -1.63b / FCF TTM 987.3m)
Total Stockholder Equity = 1.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.70% (Net Income 563.8m / Total Assets 4.47b)
RoE = 28.52% (Net Income TTM 563.8m / Total Stockholder Equity 1.98b)
RoCE = 33.78% (EBIT 695.3m / Capital Employed (Equity 1.98b + L.T.Debt 81.7m))
RoIC = 25.53% (NOPAT 537.7m / Invested Capital 2.11b)
WACC = 7.22% (E(54.5b)/V(54.7b) * Re(7.24%) + D(179.2m)/V(54.7b) * Rd(0.0%) * (1-Tc(0.23)))
Discount Rate = 7.24% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.03 | Cagr: 0.00%
[DCF] Terminal Value 77.97% ; FCFF base≈917.4m ; Y1≈1.05b ; Y5≈1.55b
[DCF] Fair Price = 138.8 (EV 23.3b - Net Debt -1.63b = Equity 24.9b / Shares 179.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 80.61 | EPS CAGR: 17.82% | SUE: -0.09 | # QB: 0
Revenue Correlation: 95.72 | Revenue CAGR: 12.30% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-07-31): EPS=0.65 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS next Quarter (2026-10-31): EPS=0.79 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2027-04-30): EPS=3.63 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+24.1% | GrowthRev=+21.4%
EPS next Year (2028-04-30): EPS=4.79 | Chg30d=+3.12% | Revisions=+40% | GrowthEPS=+31.9% | GrowthRev=+17.9%
[Analyst] Revisions Ratio: +29% (up=3, down=1)